Menatetrenone Intervention for Dialysis Patients with ArterioSclerosis

Menatetrenone Intervention for Dialysis Patients with ArterioSclerosis - MIDAS study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017119

Enrollment

120

Registered

2015-04-15

Start date

2015-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic kidney disease

Interventions

With vitamin K (menatetrenone 45 mg) Without vitamin K

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients on maintenance hemodialysis without iron deficiency anemia

Exclusion criteria

Exclusion criteria: Receiving warfarin, pregnacy, hypersensitivity, liver dysfunction, thrombosis

Design outcomes

Primary

Measure	Time frame
Bone mineral density, vascular calcification , frailty, and prognosis	—

Secondary

Measure	Time frame
Oxidative stress: malondialdehyde, 8OHdG, AOPP, pentosidine, GSH. inflammation: high-sensitivity CRP, IL-6, TNF, pentraxin, troponin T. nutrition: BMI, albumin et al.	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Dep Internal Medicine, Div Kidney and Dialysis

cherry39@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026